लोड हो रहा है...

Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells

BACKGROUND: The poor outcomes for patients diagnosed with acute myeloid leukemia (AML) are largely attributed to leukemia stem cells (LSCs) which are difficult to eliminate with conventional therapy and responsible for relapse. Thus, new therapeutic strategies which could selectively target LSCs in...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Hematol Oncol
मुख्य लेखकों: Ding, Yahui, Gao, Huier, Zhang, Yu, Li, Ye, Vasdev, Neil, Gao, Yingdai, Chen, Yue, Zhang, Quan
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2016
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5034521/
https://ncbi.nlm.nih.gov/pubmed/27658462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0327-5
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!